Current status and future directions of AI in prostate cancer detection on MRI: a special report from the ESUR prostate MRI working group authors - Scorecard - MDSpire
Clinical Scorecard: The Role of Artificial Intelligence in Prostate Cancer Detection via MRI: Insights and Future Perspectives from the ESUR Prostate MRI Working Group
At a Glance
Category
Detail
Condition
Prostate Cancer Detection
Key Mechanisms
Artificial intelligence in MRI enhances gland segmentation, PSA density calculation, and detection of clinically significant prostate cancer.
Target Population
Patients undergoing prostate MRI for cancer detection.
Care Setting
Radiological practice utilizing MRI technology.
Key Highlights
AI may equal or surpass radiologists' performance in detecting clinically significant prostate cancer.
AI systems can automate gland segmentation and reduce variability in reporting.
Real-world evidence for AI medical devices is limited and requires further validation.
AI has shown potential to decrease unproductive biopsies by improving risk assessment.
Performance of AI devices varies based on application and reader-AI interaction.
Guideline-Based Recommendations
Diagnosis
AI systems should be evaluated for clinical validity and efficacy in real-world settings.
Management
AI can assist in biopsy decision-making and improve detection rates.
Monitoring & Follow-up
Post-market surveillance of AI devices is necessary to ensure ongoing safety and effectiveness.
Risks
Challenges include automation bias and the complexities of human-AI interactions.
Patient & Prescribing Data
Patients with suspected prostate cancer undergoing MRI.
AI tools may enhance diagnostic accuracy and reduce unnecessary procedures.
Clinical Best Practices
Ensure AI devices are validated in prospective studies before clinical use.
Monitor AI performance continuously in real-world applications.
Educate radiologists on the limitations and capabilities of AI systems.
by Renato Cuocolo, Andrea Ponsiglione, Georgios Agrotis, Tristan Barrett, Giorgio Brembilla, Iztok Caglic, Hanna Falińska, Charlie Alexander Hamm, Emanuele Messina, Tobias Penzkofer, Raphaële Renard-Penna, Olivier Rouvière, Luca Russo, Evis Sala, Johannes Uhlig, Anwar R. Padhani, Maarten de Rooij
U.S. News & World Report has recognized Dana-Farber/Boston Children’s Cancer and Blood Disorders Center as the #1 pediatric cancer program in the nation in its 2026-2027 Best Children’s Hospitals report.
